Literature DB >> 6233249

The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.

A King, K Shannon, I Phillips.   

Abstract

The in-vitro activity of ciprofloxacin , a new 4-quinolone, was compared with that of norfloxacin and nalidixic acid against recent clinical isolates of medically important bacteria. Overall, ciprofloxacin and norfloxacin had similar spectra of activity, but ciprofloxacin had somewhat greater intrinsic activity against most organisms. Minimum inhibitory concentrations (MIC) were in the range 0.004-4 mg/l for Enterobacteriaceae, 0.016-2 mg/l for Pseudomonas spp., 0.004-1 mg/l for Acinetobacter, 0.004-0.016 mg/l for Haemophilus influenzae, 0.001-0.004 for gonococci, 0.004-0.03 mg/l for Cmpylobacter , 0.12-2 mg/l for staphylococci, 0.25-4 mg/l for streptococci, 1-32 mg/l for the Bacteroides fragilis group and mostly in the range 0.25-8 mg/l for other obligate anaerobes. Resistant variants could be selected readily in vitro by culture on any of the three compounds investigated. However, while the MICs of nalidixic acid were high for these variants those of ciprofloxacin and norfloxacin were much lower.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6233249     DOI: 10.1093/jac/13.4.325

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  28 in total

Review 1.  Bacterial challenges and evolving antibacterial drug strategy.

Authors:  B Watt; J G Collee
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

2.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  In vitro induction of ciprofloxacin resistance in coagulase-negative staphylococci.

Authors:  J W Hartley; B A Oppenheim
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553

4.  Interaction between ciprofloxacin and tobramycin or azlocillin against multiresistant strains of Acinetobacter anitratum in vitro.

Authors:  B P Overbeek; M Rozenberg-Arska; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

5.  Impact of oral ciprofloxacin on the faecal flora of healthy volunteers.

Authors:  R Enzensberger; P M Shah; H Knothe
Journal:  Infection       Date:  1985 Nov-Dec       Impact factor: 3.553

6.  Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth.

Authors:  A Forsgren; A Bredberg; A B Pardee; S F Schlossman; T F Tedder
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 8.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

9.  Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).

Authors:  G Verschraegen; G Claeys; A M Van den Abeele
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

Review 10.  Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1986-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.